Key result
Cardiac resynchronisation therapy improved morbidity and mortality with no statistical interaction based on symptom severity, including the 21.5% of patients who self-assessed as NYHA class I or II.
Why the study?
Does cardiac resynchronisation therapy reduce morbidity and mortality in heart failure patients with LVEF <=35% and dyssynchrony regardless of self-reported symptom severity?
RCT (n=813)
Randomized
Does cardiac resynchronisation therapy reduce morbidity and mortality in heart failure patients with LVEF <=35% and dyssynchrony regardless of self-reported symptom severity?
The prognostic benefits of CRT on morbidity and mortality in patients with moderate or severe LVSD and dyssynchrony are not significantly influenced by self-reported symptom severity.
No takes yet. Share an insight, caveat, or question.
CRT benefits patients with LVEF ≤35% and dyssynchrony irrespective of self-reported NYHA class; extends evidence to milder symptoms without interaction.
Cleland et al. (2007) conducted an RCT in Heart failure with cardiac dyssynchrony (n=813). Cardiac resynchronisation therapy (CRT) vs. Pharmacological treatment alone was evaluated on Morbidity and mortality. Cardiac resynchronisation therapy improved morbidity and mortality with no statistical interaction based on symptom severity, including the 21.5% of patients who self-assessed as NYHA class I or II.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: